What is the latest price of a box of nitrohydroxyquinoline capsules in 2025?

Nitroquinol capsule is a quinolone derivative with both antibacterial and anti-tumor activities. It is mainly used to treat urinary tract infections caused by sensitive bacteria or yeast. In 2025, the latest price of nitroquinoline capsules is approximately US$113, with a specification of 250mg*50 capsules/box, produced by MIP Pharma GmbH in Germany. The drug has not yet been launched in China and has not been included in medical insurance, but it has attracted much attention in the international market because of its unique antibacterial mechanism and dual effects.

How much is the latest price of a box of nitroquinol capsules in 2025

As a special antibacterial drug, the price of nitroquinol capsules is affected by factors such as production costs, market demand, and patent protection. In 2025, the price of the drug remains stable compared with previous years, at $113 per box.

Price components

The price of nitroquinoline capsules is mainly determined by research and development costs, production technology and market demand. As the original drug of German MIP Pharma GmbH, its production technology requires high standards, and there is currently no competition from generic drugs, so the price is relatively high. In addition, the drug's dual efficacy (antibacterial and anti-tumor) also increases its market value.

Purchase channels and precautions

Since nitroquinol capsules are not yet available in China, patients need to purchase them through formal overseas channels. When purchasing, pay special attention to the authenticity and expiration date of the medicine to avoid buying fake or substandard medicines. It is recommended to choose a qualified international pharmacy or medical institution to ensure reliable sources of medicines.

Price comparison and future trends

Compared with other similar antibacterial drugs, the price of nitroquinol capsules is at a medium level. In the future, as more generic drugs are launched and market competition intensifies, prices may fall. But at present, patients still need to bear higher treatment costs.

Global marketing status of nitroquinol capsules

The global marketing status of nitroquinoline capsules reflects its clinical application value and market potential. Currently, this drug is mainly approved for use in some countries and regions.

European market

Nitroquinol capsules are produced by MIP Pharma GmbH in Germany and have been approved for marketing in many European countries for the treatment of urinary tract infections.

Chinese market

Nitroquinol capsules have not been officially launched in mainland China, nor have they been included in the medical insurance catalog. If patients need to use it, they need to purchase it through overseas channels. As clinical demand increases in the future, the drug's approval process in China may be accelerated.

Medicine preparation for nitroquinol capsules

The medication regimen of nitroquinol capsules is relatively clear. Patients need to strictly follow the dosing plan under the guidance of a doctor and make preparations before taking the medication.

Dosage regimen

The conventional dosage for adults is 1 capsule each time, 3 times a day; when used for chronic urinary tract infection or to prevent recurrence, 1-2 capsules a day. Capsules should be swallowed with plenty of water 1 hour before meals. The entire course of treatment must be completed during the medication period, and the medication must not be stopped early due to improvement of symptoms.

Adverse reaction management

Common adverse reactions include gastrointestinal reactions (such as nausea, vomiting) and skin allergies (such as erythema, itching). Mild symptoms usually resolve on their own, but severe symptoms require prompt medical attention. Liver function and blood routine must be monitored regularly during medication.

Medication for special groups

Pregnant women, lactating women, children and patients with liver and kidney dysfunction should use nitroquinol capsules with caution. The specific medication plan needs to be formulated by the doctor based on individual circumstances, and the dose should be adjusted or medication suspended if necessary.

Nitrohydroxyquinoline capsules provide a new treatment option for patients with urinary tract infections, but its price and medication precautions still require the joint attention of patients and doctors.